151 related articles for article (PubMed ID: 38606542)
1. From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies.
Diamond A
Br J Haematol; 2024 May; 204(5):1588-1589. PubMed ID: 38606542
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
3. Langerhans cell histiocytosis.
Rodriguez-Galindo C; Allen CE
Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
[TBL] [Abstract][Full Text] [Related]
4. Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.
Bahabri A; Abla O
Expert Rev Hematol; 2024 Jun; 17(6):223-231. PubMed ID: 38721670
[TBL] [Abstract][Full Text] [Related]
5. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
[TBL] [Abstract][Full Text] [Related]
6. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.
Abla O
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):386-395. PubMed ID: 38066856
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
Jouenne F; Benattia A; Tazi A
Curr Opin Oncol; 2021 Mar; 33(2):101-109. PubMed ID: 33315630
[TBL] [Abstract][Full Text] [Related]
8. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
9. New biomarker paves the way for a clinical trial for neurodegeneration in Langerhans cell histiocytosis.
Shioda Y; Sakamoto K; Morimoto A
Br J Haematol; 2022 Aug; 198(4):623-624. PubMed ID: 35727899
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
Li Q
J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
Kobayashi M; Tojo A
Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
[TBL] [Abstract][Full Text] [Related]
12. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
[TBL] [Abstract][Full Text] [Related]
13. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
14. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis.
Brown NA; Elenitoba-Johnson KSJ
Curr Opin Pulm Med; 2018 May; 24(3):281-286. PubMed ID: 29470255
[TBL] [Abstract][Full Text] [Related]
16. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
19. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
[TBL] [Abstract][Full Text] [Related]
20. Genomic Alterations in Langerhans Cell Histiocytosis.
Rollins BJ
Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]